UAS7 & UCT Calculator

Urticaria Activity Score over 7 days (Młynek et al., 2008) and Urticaria Control Test (Weller et al., 2014)

Purpose
Patient-reported disease activity (UAS7: wheals and itch recorded daily for 7 days) and disease control over the last 4 weeks (UCT) in chronic urticaria.
Population
Chronic spontaneous urticaria. UAS7 does not capture angioedema (use AAS) or inducible urticaria (use provocation thresholds). UCT applies to all chronic urticaria subtypes. Recommended by the EAACI/GA²LEN/EuroGuiDerm/APAAACI 2022 guideline.
Formula
UAS7 = Σ over 7 days of (wheals 0–3 + itch 0–3) · 0–42. UCT = Σ of 4 items 0–4 · 0–16.
Severity thresholds
UAS7 (Stull 2017): 0 urticaria-free · 1–6 well controlled · 7–15 mild · 16–27 moderate · 28–42 severe. UCT (Weller 2014): ≥ 12 well controlled · < 12 poorly controlled · 16 complete control. Treatment goal (guideline 2022): complete control (UAS7 = 0, UCT = 16).
📅 Daily diary — last 7 days

The patient records once daily the number of wheals and the intensity of itch over the previous 24 hours. Each day scores 0–6.

Wheals (per 24 h) 0 = none · 1 = mild (< 20 wheals) · 2 = moderate (20–50 wheals) · 3 = intense (> 50 wheals or large confluent areas of wheals)
Itch 0 = none · 1 = mild (present but not annoying or troublesome) · 2 = moderate (troublesome but does not interfere with normal daily activity or sleep) · 3 = intense (severe, interferes with normal daily activity or sleep)
UAS7 (running total) 0 / 42
🎯 Urticaria Control Test — last 4 weeks

Four patient-reported items, each scored 0–4 (0 = worst, 4 = best). Total 0–16; higher = better control.

UCT (running total) 0 / 16
© The UCT is copyrighted (MOXIE GmbH, Berlin; developed at Charité – Universitätsmedizin Berlin). Use in routine clinical practice and non-funded academic research is free; a licence is required for commercial or industry-sponsored use. Wording here is a non-validated English/Spanish rendering of the published items; use the licensed validated translation for research.
📚 References
  1. Młynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–80.
  2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66.
  3. Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093–101.
  4. Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score — validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185–90.
  5. Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20–4.
  6. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365–72.
  7. Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal clinically important difference of the urticaria control test. J Allergy Clin Immunol. 2017;140(6):1710–3.
Clinical decision support only. This tool is intended to assist clinical assessment and does not replace professional judgment. Always interpret results in the context of the individual patient.